Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ProMisMe

Financiado

Bioengineered microbes as a platform for discovering chemical rescuers of diseas...

Bioengineered microbes as a platform for discovering chemical rescuers of disease-related misfolding of integral membrane proteins Protein misfolding diseases (PMDs) are a large group of human disorders caused by the misfolding of specific proteins. They include conditions with high socio-economic impact, such as Alzheimer’s disease, cystic fibrosis, obesity... ver más

30/06/2026

BIOMEDICALSCIENCES...

212K€

Presupuesto del proyecto: 212K€

Líder del proyecto

EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-19

HORIZON-WIDERA-2022-TALENTS-04-01: Fostering balanced brain circulatio... ExpectedOutcome:This action will build on the MSCA Postdoctoral Fellowships 2022 action (HORIZON-MSC...

I+D

Cerrada hace 2 años

0% 100% 100%

2 Participantes

BIOMEDICALSCIENCES RESEARCH...

211.66K€ | Lider

RESQ BIOTECH IDIOTIKI KEFALA...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Twin4Promis Twinning for Excellence in Research, Training and Innovation... 1M€ Cerrado

RYC-2009-04147 Estrategias para la corrección farmacológica de enfermedades... 192K€ Cerrado

CTQ2011-24393 INHIBICION DE LA AGREGACION DE PROTEINAS POR POLIELECTROLITO... 111K€ Cerrado

PID2019-111273RB-I00 AMPLIACION DE LA INGENIERIA METABOLICA DE SISTEMAS DE C. SAL... 157K€ Cerrado

INC-TU-2011-1094 Investigación y Desarrollo de Nuevas Plataformas Tecnológica... 166K€ Cerrado

BIO2011-26689 DESARROLLOS PARA LA APLICACION IN VIVO DE LA ADHESION SINTET... 230K€ Cerrado

Duración del proyecto: 32 meses Fecha Inicio: 2023-10-19
Fecha Fin: 2026-06-30

Líder del proyecto

EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 212K€

Descripción del proyecto Protein misfolding diseases (PMDs) are a large group of human disorders caused by the misfolding of specific proteins. They include conditions with high socio-economic impact, such as Alzheimer’s disease, cystic fibrosis, obesity and type 2 diabetes, and the majority of them remain incurable. Among the >70 PMDs, about 1/3 are caused by misfolding-prone membrane proteins (MisMPs). Despite their significance, and mainly due to the difficulties associated with MisMP overexpression, isolation and characterization, the PMD scientific community has largely overlooked MisMP-associated PMDs, thus limiting opportunities for drug discovery. In ProMisMe, we will develop engineered bacteria and yeast, which can function as broadly applicable discovery platforms for compounds that rescue MisMP misfolding. These compounds will be selected from libraries of drug-like molecules biosynthesized in these microbes using a technology that allows the facile production of tens of millions to tens of billions of different test molecules. These libraries will then be screened in the same microbial cells that produce them and the rare molecules that rescue MisMP misfolding effectively will be selected by ultrahigh-throughput screening. The effect of the selected molecules on MisMP folding will then evaluated by biochemical and biophysical methods, while their ability to reverse MisMP-induced pathogenicity will be tested in appropriate mammalian cell assays. The molecules that rescue the misfolding and associated pathogenicity of the target MisMPs will become therapeutic candidates against the corresponding diseases. This procedure will be applied for different MisMPs to identify potential therapeutics for two serious PMDs: Usher Syndrome III and Charcot-Marie-Tooth disease. Successful realization of ProMisMe will provide invaluable therapeutic leads against major diseases and a more widely applicable framework for drug discovery against diseases caused by membrane protein misfolding.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores